Pharmacokinetics of buspirone in autistic children.
Buspirone is used to treat generalized anxiety disorder in children and may be useful in developmental disorders in which brain serotonin synthesis is altered. Autistic children (13 boys, 7 girls) were given a single oral dose of 2.5 mg (2-3 years) or 5.0 mg (4-6 years). Blood was collected for 8 hours, and plasma was assayed for buspirone and its metabolite 1-pyrimidinylpiperazine (1-PP). The peak concentration of buspirone averaged 1141 +/- 748 pg/mL with a time to maximum concentration of 0.8 hours. Half-life was 1.6 +/- 0.3 hours. Peak concentrations of 1-PP were 4.5-fold higher than for buspirone. Girls had higher peak concentrations (1876 vs 746 pg/mL) for buspirone and a lower peak 1-PP/buspirone concentration ratio. These results suggest that buspirone is rapidly absorbed and eliminated in young children with extensive metabolism to 1-PP. Plasma concentrations with 2.5- to 5.0-mg doses were similar to those observed in older children receiving 7.5- to 15-mg doses.
Edwards
David J
DJ
Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA. dje@wayne.edu
Chugani
Diane C
DC
Chugani
Harry T
HT
Chehab
Jamal
J
Malian
Monica
M
Aranda
Jacob V
JV
D014151:Anti-Anxiety Agents / Q000097:blood / Q000493:pharmacokinetics*; D001321:Autistic Disorder / Q000378:metabolism*; D002065:Buspirone / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D017366:Serotonin Receptor Agonists / Q000097:blood / Q000493:pharmacokinetics*
D014151:Anti-Anxiety Agents; D017366:Serotonin Receptor Agonists; C037921:1-(2-pyrimidinyl)piperazine; D002065:Buspirone